PALO ALTO, Calif. — October 29, 2025 — Leads & Copy — BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its third-quarter financial results and business updates, reporting $120.7 million in total revenue, including $108.1 million from U.S. Attruby® net product revenue.
As of Oct. 25, 2025, 5,259 unique patient prescriptions had been written by 1,355 unique prescribers since FDA approval in November 2024. The company intends to file an NDA for BBP-418 for LGMD2I/R9 and encaleret for ADH1 with the FDA in the first half of 2026. Topline results for PROPEL 3, the Phase 3 study of infigratinib for children with achondroplasia, are expected in early 2026.
The company ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities.
BridgeBio highlighted Attruby’s impact on cardiovascular outcomes and the positive results from the FORTIFY and CALIBRATE studies. The company continues to grow the potential impact of its medicines.
BridgeBio will host its quarterly earnings call and simultaneous webcast today, October 29th 2025 at 4:30 pm ET.
Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
Chinmay Shukla, Senior Vice President, Strategic Finance & Investor Relations
ir@bridgebio.com
Source: BridgeBio Pharma, Inc.
